| 查看: 348 | 回复: 4 | |||
| 当前主题已经存档。 | |||
[交流]
求助
|
|||
| 我是做毛细管电泳的，搞药物分析，最近做盐酸氟利桂嗪，配缓冲溶液，需要知道盐酸氟利桂嗪的pka，但是都没有查到，求助虫友们……谢谢 |
回复此楼» 猜你喜欢
【长期招聘】复旦大学 AI 制药实验室 博士后招聘
已经有9人回复
-
售SCI一区T0P文章，我:8O.55.1.O.5.4,科目齐全,可+急
已经有6人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急
已经有7人回复
-
售SCI文章，我:8O.5.5.1O.54,科目全,可十急
已经有6人回复
-
售SCI一区T0P文章，我:8.O.55.1.O54,科目全,可伽急
已经有8人回复
-
售SCI一区文章，我:8.O.551.O.5.4,科目全,可伽急
已经有6人回复
-
售SCI一区T0P文章，我:8O.55.1.O.54,科目全,可伽急
已经有6人回复
-
售SCI一区T0P文章，我:8O.55.1.O.5.4,科目齐全,可+急
已经有4人回复
-
售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急
已经有6人回复
-
售一区SCI文章T0P，我:8O.551.O54,科目全,可十急
已经有6人回复
qqtan
木虫 (正式写手)
- 应助: 30 (小学生)
- 金币: 2481.3
- 散金: 3532
- 红花: 25
- 帖子: 667
- 在线: 1696.8小时
- 虫号: 82659
- 注册: 2005-07-26
- 性别: GG
- 专业: 有机合成
2楼2009-03-19 11:16:55
3楼2009-03-20 10:49:05
qqtan
木虫 (正式写手)
- 应助: 30 (小学生)
- 金币: 2481.3
- 散金: 3532
- 红花: 25
- 帖子: 667
- 在线: 1696.8小时
- 虫号: 82659
- 注册: 2005-07-26
- 性别: GG
- 专业: 有机合成
★
karl2100(金币+1,VIP+0):谢谢！ 3-21 20:05
karl2100(金币+1,VIP+0):谢谢！ 3-21 20:05
|
Monograph Number: 4170 Title: Flunarizine CAS Registry Number: 52468-60-7 CAS Name: (E)-1-[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine Additional Names: (E)-1-[bis(p-fluorophenyl)-methyl]-4-cinnamylpiperazine; 1-cinnamyl-4-(di-p-fluorobenzhydryl)piperazine Molecular Formula: C26H26F2N2 Molecular Weight: 404.49. Percent Composition: C 77.20%, H 6.48%, F 9.39%, N 6.93% Literature References: Calcium channel blocker; fluorinated deriv of cinnarizine, q.v. Prepn: P. A. J. Janssen, DE 1929330 and FR 2014487; idem, US 3773939 (1970, 1970, 1973, all to Janssen). Pharmacology: L. K. Desmedt et al., Arzneimittel-Forsch. 25, 1408 (1975); T. Godfraind, Eur. J. Pharmacol. 53, 273 (1979). Clinical studies: J. Schetz et al., Curr. Ther. Res. Clin. Exp. 23, 131 (1978); G. Rudofsky et al., Angiology 30, 479 (1979). Rheological effects in humans: J. D. Cree et al., ibid. 505. Mechanism of calcium blocking activity: T. Godfraind, Fed. Proc. 40, 2866 (1981). Clinical study in retinal vasculopathy: P. Nihard, Angiology 33, 37 (1982). Clinical trial in chronic cerebrovascular disorders: A. Agnoli et al., Int. J. Clin. Pharm. Res. 8, 189 (1988). Series of articles on absorption, distribution, excretion and metabolism: Arzneimittel-Forsch. 33, 1135-1151 (1983). Review of pharmacology, toxicology and clinical studies: B. Holmes et al., Drugs 27, 6 (1984). Derivative Type: Dihydrochloride CAS Registry Number: 30484-77-6 Trademarks: Dinaplex (Sidus); Flugeral (Italfarmaco); Flunagen (Gentili); Flunarl (Kyowa Hakko); Fluxarten (SKB); Gradient (Polifarma); Issium (Lifepharma); Mondus (Labinca); Sibelium (Janssen) Molecular Formula: C26H26F2N2.2HCl Molecular Weight: 477.43. Percent Composition: C 65.41%, H 5.91%, F 7.96%, N 5.87%, Cl 14.85% Properties: Crystals from a mixture of 2-propanol/ethanol, mp 251.5? Melting point: mp 251.5° 不好意思，只能找到这些了 [ Last edited by qqtan on 2009-3-20 at 12:38 ] |
4楼2009-03-20 12:37:20
5楼2009-03-21 08:56:38
